118 related articles for article (PubMed ID: 10520726)
1. Antagonism by pimozide of olanzapine-induced hypothermia.
Ninan I; Kulkarni SK
Fundam Clin Pharmacol; 1999; 13(5):541-6. PubMed ID: 10520726
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
Oerther S; Ahlenius S
J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals.
Ninan I; Kulkarni SK
Psychopharmacology (Berl); 1999 Feb; 142(2):175-81. PubMed ID: 10102770
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.
Deveney AM; Waddington JL
Psychopharmacology (Berl); 1996 Mar; 124(1-2):40-9. PubMed ID: 8935799
[TBL] [Abstract][Full Text] [Related]
5. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
6. Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats.
Ahlqvist J; Isacson R; Wahlestedt C; Salmi P
Eur Neuropsychopharmacol; 2003 May; 13(3):177-82. PubMed ID: 12729943
[TBL] [Abstract][Full Text] [Related]
7. Effects of D1 and D2 antagonists on basal and apomorphine decreased body temperature in mice and rats.
Chipkin RE
Pharmacol Biochem Behav; 1988 Jul; 30(3):683-6. PubMed ID: 2974995
[TBL] [Abstract][Full Text] [Related]
8. Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss.
Moy SS; Knapp DJ; Breese GR
Neuropsychopharmacology; 2001 Aug; 25(2):224-33. PubMed ID: 11425506
[TBL] [Abstract][Full Text] [Related]
9. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
10. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat.
Salmi P; Karlsson T; Ahlenius S
Eur J Pharmacol; 1994 Feb; 253(1-2):67-73. PubMed ID: 7912199
[TBL] [Abstract][Full Text] [Related]
11. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition.
Rasmussen K; Gates MR; Burger JE; Czachura JF
Neurosci Lett; 1997 Jan; 222(1):61-4. PubMed ID: 9121724
[TBL] [Abstract][Full Text] [Related]
12. Phencyclidine supersensitivity in rats with neonatal dopamine loss.
Moy SS; Breese GR
Psychopharmacology (Berl); 2002 May; 161(3):255-62. PubMed ID: 12021828
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.
Tarazi FI; Zhang K; Baldessarini RJ
J Pharmacol Exp Ther; 2001 May; 297(2):711-7. PubMed ID: 11303062
[TBL] [Abstract][Full Text] [Related]
14. Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.
Dias FR; de Mello Bastos JM; de Fátima Dos Santos Sampaio M; Carey RJ; Carrera MP
Psychopharmacology (Berl); 2013 Dec; 230(4):579-88. PubMed ID: 23846543
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
Rossi NF
Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
[TBL] [Abstract][Full Text] [Related]
16. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
Moore NA; Tye NC; Axton MS; Risius FC
J Pharmacol Exp Ther; 1992 Aug; 262(2):545-51. PubMed ID: 1354253
[TBL] [Abstract][Full Text] [Related]
17. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia.
Sachdev PS; Saharov T
Psychiatry Res; 1998 Dec; 81(3):323-32. PubMed ID: 9925183
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
Bymaster FP; Hemrick-Luecke SK; Perry KW; Fuller RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):87-94. PubMed ID: 8935803
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor subtypes and formalin test analgesia.
Morgan MJ; Franklin KB
Pharmacol Biochem Behav; 1991 Oct; 40(2):317-22. PubMed ID: 1687167
[TBL] [Abstract][Full Text] [Related]
20. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
